Statin Use and the Progression of Parkinson’s Disease: A Population-Based Cohort Study
Author(s)
Junsung Nam, Doctor of Pharmacy1, Hyun Woo Lee, Doctor of Pharmacy1, Seungyeon Kim, PhD2, Yun Mi Yu, PhD1.
1Yonsei University, Incheon, Korea, Republic of, 2Dankook University, Cheonan, Korea, Republic of.
1Yonsei University, Incheon, Korea, Republic of, 2Dankook University, Cheonan, Korea, Republic of.
OBJECTIVES: This study aimed to evaluate the association between statin use and the progression of Parkinson's disease (PD).
METHODS: We conducted a retrospective cohort study using the Korean Health Insurance Review and Assessment (HIRA) database. Patients aged 50-79 years who were newly diagnosed with PD between 2009 and 2014 were included. Statin users and non-users were matched 1:1 using propensity scores (PS) based on age, sex, insurance type, comorbidities, and concomitant medications. Statin users were further classified as previous or new users based on statin prescriptions within 1 year prior to the index date. Cox proportional hazards regression models were used to assess the association between statin use and PD progression.
RESULTS: After the eligibility assessment and PS matching, 13,830 patients were included in the analysis, with a mean follow-up duration of 7.8 ± 1.8 years. Statin use was significantly associated with a reduced risk of mortality (hazard ratio [HR], 0.59; 95% confidence interval [CI], 0.55-0.64). Both previous users (HR, 0.57; 95% CI, 0.52-0.62) and new users (HR, 0.62; 95% CI, 0.56-0.70) had significantly lower mortality risks compared to non-users. Subgroup analyses stratified by age, sex, and comorbidities consistently showed reduced mortality risk in statin users across all groups.
CONCLUSIONS: These findings suggest that statins may have disease-modifying potential and could slow the progression of PD.
METHODS: We conducted a retrospective cohort study using the Korean Health Insurance Review and Assessment (HIRA) database. Patients aged 50-79 years who were newly diagnosed with PD between 2009 and 2014 were included. Statin users and non-users were matched 1:1 using propensity scores (PS) based on age, sex, insurance type, comorbidities, and concomitant medications. Statin users were further classified as previous or new users based on statin prescriptions within 1 year prior to the index date. Cox proportional hazards regression models were used to assess the association between statin use and PD progression.
RESULTS: After the eligibility assessment and PS matching, 13,830 patients were included in the analysis, with a mean follow-up duration of 7.8 ± 1.8 years. Statin use was significantly associated with a reduced risk of mortality (hazard ratio [HR], 0.59; 95% confidence interval [CI], 0.55-0.64). Both previous users (HR, 0.57; 95% CI, 0.52-0.62) and new users (HR, 0.62; 95% CI, 0.56-0.70) had significantly lower mortality risks compared to non-users. Subgroup analyses stratified by age, sex, and comorbidities consistently showed reduced mortality risk in statin users across all groups.
CONCLUSIONS: These findings suggest that statins may have disease-modifying potential and could slow the progression of PD.
Conference/Value in Health Info
2025-09, ISPOR Real-World Evidence Summit 2025, Tokyo, Japan
Value in Health Regional, Volume 49S (September 2025)
Code
RWD92
Topic Subcategory
Health & Insurance Records Systems
Disease
SDC: Neurological Disorders